Phase II study of docetaxel and oxaliplatin in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer (NSCLC).

e18022 Background: Docetaxel (D) is active in advanced NSCLC. Bevacizumab (B) enhances conventional chemotherapy with increased response rate and prolonged survival. The study objective is to evalu...